CEO Executive AssistantCell and gene therapy companies occupy a uniquely challenging position in the life sciences landscape. The science is transformative, offering the potential for curative or substantially disease-modifying treatments for conditions that conventional medicines cannot adequately address. But the operational complexity of developing, manufacturing, and delivering these therapies is extraordinary, and the regulatory and commercial pathways are in many cases still being established.
For CEOs of cell and gene therapy companies, this combination of transformative potential and operational complexity creates extreme delegation demands. The technical functions, from vector manufacturing to cell processing to patient-specific supply chain logistics, require deep specialized expertise that most CEOs cannot personally master. And yet the strategic decisions about program selection, manufacturing strategy, regulatory approach, and commercial pathway require CEO-level judgment and authority.
This guide gives cell and gene therapy CEOs a practical framework for delegating the technical and operational dimensions of the business while maintaining the strategic leadership that determines organizational success.
The Cell and Gene Therapy Operational Context
Before describing the delegation strategies, it is worth understanding what makes cell and gene therapy operations uniquely complex.
Manufacturing is the most critical challenge. Cell and gene therapy manufacturing, whether viral vector production, ex vivo cell engineering, or in vivo gene delivery, is among the most technically demanding biomanufacturing in any industry. Vector manufacturing quality directly affects clinical efficacy and safety. Patient-specific cell therapy manufacturing creates unique supply chain challenges. Manufacturing reliability is often the limiting factor for both clinical programs and commercial scale.
Regulatory pathways are evolving. The regulatory frameworks for cell and gene therapies continue to evolve at FDA, EMA, and other agencies. Navigating this regulatory landscape requires both deep regulatory expertise and strong agency relationships.
Clinical programs are high-risk and high-cost. Small patient populations with serious diseases, complex dosing logistics, and high manufacturing costs per patient make clinical programs particularly capital-intensive. Program failure is financially severe.
Commercial models are unprecedented. The commercialization of curative or single-administration therapies requires commercial models, including outcomes-based pricing, patient selection infrastructure, and authorized treatment center networks, that have no direct precedent in conventional pharmaceuticals.
Talent scarcity. Technical expertise in cell and gene therapy, including manufacturing scientists, vector engineers, regulatory specialists, and clinical operations professionals with advanced therapy experience, is scarce and highly competitive.
Delegating Cell and Gene Therapy Manufacturing
Manufacturing delegation is both the most important and most technically complex delegation decision for cell and gene therapy CEOs.
VP of Manufacturing or Head of Process Development. This leader should own all manufacturing functions: vector manufacturing or cell processing operations, process development and scale-up, quality control and release testing, technology transfer, and manufacturing quality systems. The CEO is engaged when manufacturing strategy decisions require major capital commitments or when manufacturing quality issues create program risks.
Quality Director. A dedicated quality director should own the manufacturing quality management system: GMP compliance, quality control laboratory operations, deviations and CAPAs, batch release, and regulatory inspections. The quality function must have genuine organizational independence to maintain GMP standards without commercial pressure.
Supply chain function. For autologous cell therapies in particular, the patient-specific supply chain, including patient sample collection, transport, manufacturing scheduling, and product delivery, is a mission-critical operational function. A dedicated supply chain director should own this function with deep expertise in advanced therapy logistics.
CMO strategy. Many cell and gene therapy companies partner with CDMOs for manufacturing. Managing CDMO relationships requires dedicated alliance management skills. A business development or manufacturing partnership manager should own CDMO relationship management, with the CEO engaged for major strategic decisions about manufacturing partnerships.
Regulatory Affairs Delegation in Advanced Therapies
The regulatory landscape for cell and gene therapies requires specialized expertise. FDA’s Office of Tissues and Advanced Therapies and EMA’s Committee for Advanced Therapies have specific expectations, evolving guidances, and regulatory pathways that differ from conventional pharmaceuticals.
A chief regulatory officer or VP of regulatory affairs with advanced therapy experience should own regulatory strategy and operations: designing regulatory paths for each program, managing agency interactions at the program level, overseeing regulatory submission preparation, and managing post-approval commitments.
The CEO engages with regulatory affairs at the strategic level: BLA strategy decisions, significant agency interactions at the leadership level, and major regulatory decisions that affect pipeline timelines or business strategy.
For a broader framework on how pharma and biotech CEOs structure delegation across all functions, see our resource on pharma CEO guide.
Clinical Development Delegation for Advanced Therapies
Clinical programs in cell and gene therapy require specialized clinical operations expertise: managing specialized clinical sites, overseeing complex dosing logistics, monitoring patients for delayed adverse events, and integrating manufacturing scheduling with clinical timelines.
A chief medical officer with advanced therapy clinical experience should own the clinical development function. Program directors and clinical team leaders should manage individual trial execution, including site management, patient recruitment, safety monitoring, and CRO oversight.
The CEO engages with clinical development at major stage gate decisions: advancement from Phase 1 to Phase 2, major protocol modifications based on emerging safety or efficacy data, and go/no-go decisions that require strategic resource reallocation.
Patient Access and Commercial Delegation
Cell and gene therapy commercialization requires a fundamentally different commercial model than conventional pharmaceuticals. The commercial strategy for a curative therapy with a six-figure or seven-figure per-patient price point, a small patient population, and a complex delivery pathway has no direct analog in the pharmaceutical industry.
A chief commercial officer or head of commercial should own commercial strategy and operations: patient identification and referral programs, authorized treatment center development, market access and reimbursement strategy, patient support services, and commercial launch planning.
The CEO engages with commercial strategy at the level of major decisions: pricing strategy, market access approach, commercial partnership decisions, and investor communications about commercial strategy. Operational commercial management belongs with the CCO.
Partnership and Alliance Delegation
Cell and gene therapy companies often depend on partnerships for manufacturing capacity, vector technology access, delivery technology, and in some cases clinical development. Managing these partnerships requires dedicated attention.
A VP of business development or head of alliances should own partnership strategy and operations: identifying and evaluating partnership opportunities, managing due diligence processes, overseeing ongoing alliance operations, and maintaining partner relationships at the working level.
The CEO maintains personal relationships with partner company C-suite executives and engages when major partnership decisions require CEO authority.
Long-Duration Safety Monitoring
Cell and gene therapies often require long-term patient follow-up to monitor for delayed adverse events, including insertional mutagenesis for integrating vectors and immune responses over extended periods. This long-duration safety monitoring is a significant operational commitment.
A pharmacovigilance and safety function should own long-term safety surveillance: designing follow-up protocols, managing patient registries, analyzing safety data, and managing regulatory safety reporting. The CEO is engaged when significant safety signals require strategic organizational response.
Intellectual Property Strategy
Cell and gene therapy IP landscapes are complex: foundational gene editing patents, delivery system IP, manufacturing process IP, and product-specific IP can all be relevant to a single program. Managing this IP landscape requires specialized expertise.
A chief IP counsel or VP of intellectual property should own IP strategy: freedom to operate analysis, patent prosecution, licensing strategy, and IP litigation management. The CEO engages when major IP decisions require strategic authority: significant licensing transactions, IP litigation with strategic implications, and partnerships that involve significant IP transfers.
Investor Relations in Advanced Therapies
Investor communications for cell and gene therapy companies require communicating transformative science in ways that are scientifically credible, appropriately optimistic, and realistic about the technical and commercial challenges.
The CEO is the primary investor communicator. An IR director and medical communications team should prepare investor materials: pipeline slides, program updates, clinical data summaries, and manufacturing milestone communications. The CEO reviews and presents these materials.
According to McKinsey and Company, cell and gene therapy CEOs who invest in specialized functional leadership teams and maintain clear CEO-level engagement at strategic decision points achieve significantly faster program advancement and better capital market outcomes than those who remain operationally enmeshed across all functions.
Building a Delegation Culture in Advanced Therapy Organizations
Cell and gene therapy organizations attract scientists and clinicians who are deeply passionate about the transformative potential of their work. This passion is a powerful organizational asset, but it can also create resistance to delegation, as individuals feel that they personally must be involved in every decision that affects the therapy they have dedicated their careers to.
The CEO must build a culture where delegation is understood as an expression of organizational trust and a mechanism for achieving greater impact, not as distancing oneself from the mission. Scientists who develop and execute programs with genuine authority, within a framework of strategic direction and governance oversight, are more productive and more fulfilled than those whose work is micromanaged.
The cell and gene therapy CEO who builds this culture, while maintaining their own discipline about staying at the strategic rather than operational level, creates an organization capable of advancing the most technically demanding and most consequential therapies in modern medicine.
For guidance on delegating the drug pipeline management that is central to all cell and gene therapy companies, see our resource on pharma drug pipeline.
The patients with rare diseases, inherited disorders, and cancers who need cell and gene therapies deserve organizations led by CEOs who are thinking strategically about how to reach them. That is the ultimate argument for building a delegation model that frees the CEO to lead at the highest level.
Related Reading
For further context, explore Delegation Strategies for Asset Management CEO and Delegation Strategies for Automotive CEO: Digital Retail.